



Contents lists available at ScienceDirect

## Bioorganic &amp; Medicinal Chemistry Letters

journal homepage: [www.elsevier.com/locate/bmcl](http://www.elsevier.com/locate/bmcl)

## D-Amino acid oxidase inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1H)-one scaffold

Niyada Hin<sup>a</sup>, Bridget Duvall<sup>a</sup>, James F. Berry<sup>a,b</sup>, Dana V. Ferraris<sup>a,c</sup>, Rana Rais<sup>a,b</sup>, Jesse Alt<sup>a</sup>, Camilo Rojas<sup>a,d</sup>, Barbara S. Slusher<sup>a,b</sup>, Takashi Tsukamoto<sup>a,b,\*</sup>

<sup>a</sup> Johns Hopkins Drug Discovery Program, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA

<sup>b</sup> Department of Neurology, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA

<sup>c</sup> Department of Chemistry, McDaniel College, 2 College Hill, Westminster, MD 21157, USA

<sup>d</sup> Department of Molecular and Comparative Pathobiology, Johns Hopkins University, 855 North Wolfe Street, Baltimore, MD 21205, USA

## ARTICLE INFO

## Article history:

Received 23 December 2015

Revised 19 February 2016

Accepted 22 February 2016

Available online xxx

## Keywords:

D-Amino acid oxidase

Flavoenzyme

Pharmacokinetics

Schizophrenia

D-Serine

## ABSTRACT

A series of 3-substituted 5-hydroxy-1,2,4-triazin-6(1H)-one derivatives were designed and synthesized as a new class of D-amino acid oxidase (DAAO) inhibitors. Some of the newly synthesized derivatives showed potent inhibitory activity against human DAAO with IC<sub>50</sub> values in the nanomolar range. Among them, 6-hydroxy-3-phenethyl-1,2,4-triazin-5(2H)-one **6b** and 3-((6-fluoronaphthalen-2-yl)methylthio)-6-hydroxy-1,2,4-triazin-5(2H)-one **6m** were found to be metabolically stable in mouse liver microsomes. In addition, compound **6b** was found to be orally available in mice and able to enhance plasma D-serine levels following its co-administration with D-serine compared to the oral administration of D-serine alone.

© 2016 Elsevier Ltd. All rights reserved.

D-Amino acid oxidase (DAAO, EC 1.4.3.3) catalyzes the oxidative deamination of neutral D-amino acids including D-serine, a co-agonist at the glycine modulatory site of NMDA receptors. Because of the implication that hypofunction of NMDA receptors plays an important role in the pathophysiology of schizophrenia, there has been considerable efforts in developing DAAO inhibitors as a pharmacological approach for increasing D-serine and facilitating NMDA receptor-mediated neurotransmission. DAAO has been also implicated as a potential therapeutic target for the treatment of chronic pain since hydrogen peroxide, a reactive oxygen species co-generated by DAAO, is believed to contribute to pain hypersensitivity.<sup>1</sup> In the past decade, a wide variety of DAAO inhibitors have been identified by several research groups.<sup>2,3</sup> As shown in Figure 1, newer scaffolds of DAAO inhibitors contain a branched chain, which occupies the secondary pocket adjacent to the active site of DAAO recognized by the crystal structure of human DAAO in complex with imino-DOPA.<sup>4</sup> For example, our group exploited this secondary binding site using kojic acid derivatives represented by compound **1**.<sup>5</sup> Similarly, a group at Astellas reported potent DAAO inhibitors including **2a–b** based on a 4-hydroxypyridazin-3(2H)-one scaffold with a phenethyl group extending to the secondary


binding site.<sup>6</sup> 2-Substituted 6-hydroxy-1,2,4-triazine-3,5(2H,4H)-diones such as **3** exhibited not only potent DAAO inhibitory activity but also improved metabolic stability compared to **1–2** in liver microsomes.<sup>7</sup> This secondary binding site was also exploited by carboxylate-based DAAO inhibitors such as **4**<sup>8</sup> and **5**.<sup>9</sup> In the search for a new class of DAAO inhibitors, we have examined a variety of scaffolds that may serve as a bioisostere for the carboxylic acid moiety interacting with the active site of DAAO.

We found that the 5-hydroxy-1,2,4-triazin-6(1H)-one moiety can serve as an effective carboxylate isostere and that its 3-position can be utilized to attach a branched chain that extends into the secondary binding site of DAAO. These derivatives of **6** were found to potentially inhibit human DAAO with IC<sub>50</sub> values in the nanomolar range. In this Letter, we describe the SAR for this new class of DAAO inhibitors as well as the pharmacological properties of selected compounds, including metabolic stability, oral pharmacokinetics, and effects on plasma levels of D-serine in mice following oral co-administration.

Synthetic methods of 3-substituted 5-hydroxy-1,2,4-triazin-6(1H)-one derivatives **6a–o** are illustrated in Scheme 1. 3-Arylalkyl derivatives **6a–c** were prepared by first treating nitriles **7a–c** with hydrogen chloride gas to form the corresponding acetimidate **8a–c**.<sup>10</sup> Subsequent reaction with methyl chloroacetate in the presence of DIEA, followed by treatment with hydrazine afforded

\* Corresponding author. Tel.: +1 410 614 0982; fax: +1 410 614 0659.

E-mail address: [ttsukamoto@jhmi.edu](mailto:ttsukamoto@jhmi.edu) (T. Tsukamoto).




**Figure 1.** Representative known DAAO inhibitors **1–5** and 3-substituted 5-hydroxy-1,2,4-triazin-6(1H)-one derivatives **6**.

the desired products **6a–c**. 3-Arylalkylthio derivatives **6d–f** were prepared from thiosemicarbazide **9**, which was condensed with glyoxylic acid and subsequently reacted with arylalkyl bromide to afford 3-arylalkylthio-1,2,4-triazin-5(4H)-ones **10d–f**.<sup>11</sup> Oxidation of the 6-carbon with bromine<sup>12</sup> provided the final products **6d–f**. The final oxidation step, however, produced sulfoxide derivatives as by-products that often made the purification of the desired products difficult. To this end, we developed an alternative route to 3-arylalkylthio derivatives, devoid of an oxidation step. Thiosemicarbazide **9** was condensed with diethyl oxalate to form 5-hydroxy-3-mercapto-1,2,4-triazin-6(1H)-one **11** in situ, which was reacted with alkyl bromide to obtain the final products **6g–o**. Although the yields of the new synthetic procedure were poor across all the derivatives (8–21%), the one-pot preparative method was technically simpler and generated no inseparable by-products.

The inhibitory potency of the synthesized compounds were determined using recombinant human DAAO as previously reported.<sup>13</sup> In vitro DAAO inhibitory data are summarized in Table 1. 5-Hydroxy-1,2,4-triazin-6(1H)-one derivatives containing a variety of substituents at the 3-position displayed varying degrees of inhibitory potency against DAAO. All compounds but **6f** were found to be potent DAAO inhibitors with  $IC_{50}$  values in the nanomolar range. In general, the SAR trends are similar to those of 4-hydroxypyridazin-3(2H)-one and 6-hydroxy-1,2,4-triazine-3,5(2H,4H)-dione derivatives.<sup>6,7</sup> Two-unit chains,  $-CH_2CH_2-$  and  $-CH_2S-$  appear to be very effective linkers connecting the aryl group and the 5-hydroxy-1,2,4-triazin-6(1H)-one moiety, providing some of the most potent DAAO inhibitors within the series.

Many of the derivatives containing a benzylthio group at the 3-position were particularly potent DAAO inhibitors ( $IC_{50} < 100$  nM)



**Scheme 1.** Synthesis of 3-substituted 5-hydroxy-1,2,4-triazin-6(1H)-one derivatives **6a–o**. Reagents and conditions: (a) HCl (gas), MeOH/hexanes, 0 °C to rt, 86–97%; (b) (i) methyl chlorooacetate, DIEA, THF, 0 °C, (ii)  $NH_2NH_2 \cdot H_2O$ , 0 °C, 13–96%; (c) (i) 80% aq EtOH, 70 °C, (ii) glyoxylic acid, 80% aq EtOH, 70 °C, (iii)  $R^2Br$ , NaOH, 80 °C, 23–32%; (d)  $Br_2$ , (3 drops),  $H_2O$ , rt, 9–16%; (e) (i) NaOMe (25% soln in MeOH), diethyl oxalate, 65 °C, (ii)  $R^2Br$ , rt, 50 °C, 8–21%.

**Table 1**  
Inhibition of human DAAO by 3-substituted 5-hydroxy-1,2,4-triazin-6(1H)-one derivatives **6a–o**

Compd	Structure	$IC_{50}^a$ ( $\mu M$ )
<b>6a</b>		0.07
<b>6b</b>		0.06
<b>6c</b>		4.0
<b>6d</b>		0.1
<b>6e</b>		0.3
<b>6f</b>		40.0
<b>6g</b>		0.03
<b>6h</b>		0.05
<b>6i</b>		0.05
<b>6j</b>		0.09
<b>6k</b>		0.7
<b>6l</b>		0.6
<b>6m</b>		0.03
<b>6n</b>		0.2
<b>6o</b>		0.06

<sup>a</sup> Assay methods are described in Supporting information.

as represented by **6g–j**, **6m**, and **6o**. Substitutions at the phenyl ring of these compounds are generally well tolerated, reflecting the adequate space available at the secondary binding site. There seems to be a preference for linear substituents at this binding site. For instance, *para*-phenyl derivative **6j** was 8-fold more potent than the corresponding *meta*-phenyl derivative **6k**. Further, incorporation of a fused ring such as naphthyl (**6m**) benzisoxazole (**6n**), or 1,3-benzodioxole (**6o**) also produced potent DAAO inhibitors,


further underscoring the high steric tolerance at the secondary binding site.

The proposed binding mode of **6b** (white) to the active site of DAAO is illustrated in Figure 2 using the crystal structure of DAAO in complex with **2a** (cyan)<sup>6</sup> as a template. A key hydrogen bond is observed between Tyr<sup>228</sup> and Arg<sup>283</sup> and the  $\alpha$ -hydroxycarbonyl moiety of **6b**. An additional interaction is observed with the nitrogen at the 1-position of the 5-hydroxy-1,2,4-triazin-6(1H)-one moiety and the carbonyl of Gly<sup>313</sup>. A similar interaction exists in the crystal structure of human DAAO with **2a**. The high inhibitory potency retained by compounds **6j** and **6m–o** bearing a sterically hindered substituent at the 3-position can be explained by the spacious pocket created as a result of the movement of Tyr<sup>224</sup> away from the active site seen in the crystal structure of DAAO in complex with **2a**.<sup>6</sup>

We have previously reported that some DAAO inhibitors possessing an  $\alpha$ -hydroxycarbonyl moiety as a carboxylate bioisostere are prone to glucuronidation in liver microsomes in the presence of UDPGA.<sup>7,14</sup> For example, as shown in Table 2, compound **1** was extensively glucuronidated within 60 min. In contrast, compound **2b** exhibited some degree of metabolic stability while compound **3** displayed complete resistance to glucuronidation. We tested the metabolic stability of two 5-hydroxy-1,2,4-triazin-6(1H)-one derivatives **6b** and **6m** in liver microsomes. As shown in Table 2, both DAAO inhibitors were found to be resistant to glucuronidation. This is in good agreement with the previous findings that that increased topological polar surface area (tPSA) of the carboxylate bioisostere moiety contributes to higher resistance to glucuronidation.<sup>7,14</sup> The susceptibility to glucuronidation, however, may also depend on other factors such as the extent of electron delocalization and keto–enol tautomerism. Both **6b** and **6m** were also stable in mouse liver microsomes in the presence of NADPH, a cofactor for CYP-dependent oxidation.

The plasma levels of **6b** over time following oral administration (30 mg/kg) in mice are shown in Figure 3. Compound **6b** was quickly absorbed and achieved its  $C_{max}$  at 30 min after administration. The overall exposure calculated from the area under the curve ( $AUC_{0-6h}$ ) was 8.07  $\mu\text{g}\cdot\text{h}/\text{mL}$ . Binding of compound **6b** to mouse plasma protein was found to be 74%. Considering the high inhibitory potency of **6b**, sufficient unbound drug appears to be available for inhibition of peripheral DAAO at least for the first 3 h.

Given the reasonable plasma exposure by the oral route, we subsequently evaluated the effects of **6b** on D-serine plasma pharmacokinetics following oral co-administration (both at 30 mg/kg, po). As shown in Figure 4, the plasma clearance of D-serine was




**Figure 2.** Proposed binding mode of **6b** (white) to the active site of DAAO (PDB: 3W4K). Key residues and FAD are shown in green and yellow, respectively. Hydrogen-bonding interactions between **6b** and the key residues are shown as gray dashed lines. Compound **2a** (cyan) of 3W4K is also shown.

**Table 2**  
Metabolic stability of DAAO inhibitors in mouse liver microsomes


Compd	tPSA <sup>a</sup> (Å)	% remaining after 60 min	
		w/UDPGA	w/NADPH
<b>1</b>	47	5	ND <sup>b</sup>
<b>2b</b>	62	59	92
<b>3</b>	82	>99	>99
<b>6b</b>	74	98	79
<b>6m</b>	74	95	91

<sup>a</sup> tPSA of the carboxylate bioisostere moiety.

<sup>b</sup> Not determined.



**Figure 3.** Plasma levels of **6b** following oral administration of (30 mg/kg, po), in mice.



**Figure 4.** Effect of compound **6b** (30 mg/kg, po) on plasma pharmacokinetics of oral D-serine (30 mg/kg, po) in mice.

nearly arrested for the first 3 h. This is consistent with the plasma pharmacokinetics of **6b** in mice. After 3 h, the plasma D-serine levels started to decline with a clearance rate similar to that of D-serine alone treatment, presumably due to the insufficient free fraction of **6b** available for peripheral DAAO inhibition. Overall, co-administration of D-serine with DAAO inhibitor **6b** resulted in a 1.7 fold increase in the D-serine  $AUC_{0-6h}$  (74.2  $\mu\text{g}\cdot\text{h}/\text{ml}$ ) compared with D-serine treatment alone (43.3  $\mu\text{g}\cdot\text{h}/\text{ml}$ ). Given the previously reported cross-species variation in  $IC_{50}$  values between human and rat forms of DAAO,<sup>15</sup> however, caution needs to be taken in establishing the PK/PD relationship in mice as we have not measured the inhibitory potency of **6b** in mouse DAAO.

The 3-substituted derivatives of 5-hydroxy-1,2,4-triazin-6(1H)-one represent a new class of DAAO inhibitors with potent inhibitory activity and substantial microsomal metabolic stability.

Additionally, we have demonstrated the oral co-administration of a new DAAO inhibitor **6b** with D-serine can improve plasma exposure to D-serine compared with D-serine administration alone. The degree of enhancement in plasma D-serine levels (1.7-fold) was, however, lower than that of compound **3** based on a 6-hydroxy-1,2,4-triazine-3,5(2*H*,4*H*)-dione scaffold (2.2-fold) previously reported.<sup>7</sup> This is in a good agreement with the slightly lower AUC value for **6b** (8.07  $\mu\text{g}^*\text{h}/\text{mL}$ ) following oral administration relative to that of **3** (12.9  $\mu\text{g}^*\text{h}/\text{mL}$ ).<sup>7</sup> Nevertheless, the enhancement of plasma D-serine levels achieved by **6b** should be sufficient to produce pharmacological effects of D-serine in the CNS as a similar plasma D-serine exposure enhancing effect of another DAAO inhibitor, 6-chloro-1,2-benzisoxazol-3(2*H*)-one (CBIO),<sup>16</sup> resulted in attenuation of dizocilpine-induced prepulse inhibition deficits in a mouse model schizophrenia.<sup>17</sup>

The SAR data summarized in Table 1 highlight considerable steric tolerance for substituents at the 3-position that exists in the secondary binding site of DAAO, which can be further explored for improved potency. Additionally, recent findings by Terry-Lorenzo et al. suggest that the active-site lid formed by amino acids 216–224 has some degree of flexibility and undergoes conformational rearrangements depending on the ligand structures.<sup>9</sup> Of particular interest is the engagement of Tyr<sup>55</sup> in ligand interaction facilitated by the movement of the active-site lid as seen in the co-crystal structure of compound **5** bound to DAAO (PDB: 4QFD).<sup>9</sup> Effective exploitation of this dynamic structural feature may lead to further improvement in inhibitory potency within the new series of DAAO inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1*H*)-one scaffold.

## Acknowledgments

This work was in part supported by the National Institutes of Health (R01MH091387 to T.T.) and the Johns Hopkins Brain Science Institute.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2016.02.068>.

## References and notes

- Lu, J. M.; Gong, N.; Wang, Y. C.; Wang, Y. X. *Br. J. Pharmacol.* **2012**, *165*, 1941.
- Ferraris, D. V.; Tsukamoto, T. *Curr. Pharm. Des.* **2011**, *17*, 103.
- Sacchi, S.; Rosini, E.; Pollegioni, L.; Molla, G. *Curr. Pharm. Des.* **2013**, *19*, 2499.
- Kawazoe, T.; Tsuge, H.; Imagawa, T.; Aki, K.; Kuramitsu, S.; Fukui, K. *Biochem. Biophys. Res. Commun.* **2007**, *355*, 385.
- Raje, M.; Hin, N.; Duvall, B.; Ferraris, D. V.; Berry, J. F.; Thomas, A. G.; Alt, J.; Rojas, C.; Slusher, B. S.; Tsukamoto, T. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 3910.
- Hondo, T.; Warizaya, M.; Niimi, T.; Namatame, I.; Yamaguchi, T.; Nakanishi, K.; Hamajima, T.; Harada, K.; Sakashita, H.; Matsumoto, Y.; Orita, M.; Takeuchi, M. *J. Med. Chem.* **2013**, *56*, 3582.
- Hin, N.; Duvall, B.; Ferraris, D.; Alt, J.; Thomas, A. G.; Rais, R.; Rojas, C.; Wu, Y.; Wozniak, K. M.; Slusher, B. S.; Tsukamoto, T. *J. Med. Chem.* **2015**, *58*, 7258.
- Hopkins, S. C.; Heffernan, M. L.; Saraswat, L. D.; Bowen, C. A.; Melnick, L.; Hardy, L. W.; Orsini, M. A.; Allen, M. S.; Koch, P.; Spear, K. L.; Foglesong, R. J.; Soukri, M.; Chytil, M.; Fang, Q. K.; Jones, S. W.; Varney, M. A.; Panatier, A.; Oliet, S. H.; Pollegioni, L.; Piubelli, L.; Molla, G.; Nardini, M.; Large, T. H. *J. Med. Chem.* **2013**, *56*, 3710.
- Terry-Lorenzo, R. T.; Chun, L. E.; Brown, S. P.; Heffernan, M. L.; Fang, Q. K.; Orsini, M. A.; Pollegioni, L.; Hardy, L. W.; Spear, K. L.; Large, T. H. *Biosci. Rep.* **2014**, *34*, 487.
- Connolly, D. J.; Lacey, P. M.; McCarthy, M.; Saunders, C. P.; Carroll, A. M.; Goddard, R.; Guiry, P. J. *J. Org. Chem.* **2004**, *69*, 6572.
- Mizutani, M.; Sanemitsu, Y.; Tamaru, Y.; Yoshida, Z. *J. Org. Chem.* **1983**, *48*, 4585.
- Brown, D.; Jones, R. *Aust. J. Chem.* **1972**, *25*, 2711.
- Ferraris, D.; Duvall, B.; Ko, Y. S.; Thomas, A. G.; Rojas, C.; Majer, P.; Hashimoto, K.; Tsukamoto, T. *J. Med. Chem.* **2008**, *51*, 3357.
- Zimmermann, S. C.; Rais, R.; Alt, J.; Burzynski, C.; Slusher, B. S.; Tsukamoto, T. *ACS Med. Chem. Lett.* **2014**, *5*, 1251.
- Duplantier, A. J.; Becker, S. L.; Bohanon, M. J.; Borzilleri, K. A.; Chrnyk, B. A.; Downs, J. T.; Hu, L. Y.; El-Kattan, A.; James, L. C.; Liu, S.; Lu, J.; Maked, N.; Mansour, M. N.; Mente, S.; Piotrowski, M. A.; Sakya, S. M.; Sheehan, S.; Steyn, S. J.; Strick, C. A.; Williams, V. A.; Zhang, L. *J. Med. Chem.* **2009**, *52*, 3576.
- Rais, R.; Thomas, A. G.; Wozniak, K.; Wu, Y.; Jaaro-Peled, H.; Sawa, A.; Strick, C. A.; Engle, S. J.; Brandon, N. J.; Rojas, C.; Slusher, B. S.; Tsukamoto, T. *Drug Metab. Dispos.* **2012**, *40*, 2067.
- Hashimoto, K.; Fujita, Y.; Horio, M.; Kunitachi, S.; Iyo, M.; Ferraris, D.; Tsukamoto, T. *Biol. Psychiatry* **2009**, *65*, 1103.